Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 10, 2018

Primary Completion Date

April 27, 2020

Study Completion Date

May 18, 2023

Conditions

Clear Cell Renal Cell Carcinoma

Interventions

DRUG

Sitravatinib

Sitravatinib oral capsule administered daily for 6-8 weeks in segments 1 and 2.

DRUG

Nivolumab

Nivolumab administered as 240 mg IV every 2 weeks for 4-6 weeks in segment 2.

Trial Locations (1)

MD Anderson Cancer Center, Houston